A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
NCT06727630 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2024-12-11
Summary
This is a Phase Ib, open-label study to determine the safety and preliminary efficacy of PRJ1-3024 in China subjects with unresectable local advanced or metastatic melanoma
Conditions
Interventions
- DRUG
-
PRJ1-3024
PRJ1-3024 is provided as capsules and is administered orally once a day
Sponsors & Collaborators
-
Zhuhai Yufan Biotechnologies Co., Ltd
lead INDUSTRY
Principal Investigators
-
Hui Ouyang, Dr. · VP
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-14
- Primary Completion
- 2025-04-30
- Completion
- 2025-10-30
Countries
- China
Study Locations
More Related Trials
-
A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
NCT02975700 ·Status: COMPLETED ·Phase: NA
-
Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)
NCT03284424 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
NCT04625205 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
NCT04653038 ·Status: TERMINATED ·Phase: PHASE1
-
Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
NCT04472806 ·Status: UNKNOWN ·Phase: PHASE2
-
A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma
NCT01164891 ·Status: COMPLETED ·Phase: PHASE1
-
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
NCT03430297 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
NCT05877430 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
AMT-253 in Patients With Advanced Solid Tumours
NCT06209580 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
NCT01253564 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
NCT05732805 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of RO5185426 in Patients With Metastatic Melanoma
NCT01248936 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma
NCT01455103 ·Status: WITHDRAWN ·Phase: PHASE1
-
OH2 Injection in Melanoma
NCT05868707 ·Status: RECRUITING ·Phase: PHASE3
-
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
NCT05104801 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
NCT02723006 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
NCT00057616 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
NCT05823246 ·Status: UNKNOWN ·Phase: PHASE2
-
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
NCT06717126 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
NCT03153085 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
NCT06041802 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
NCT03064763 ·Status: COMPLETED ·Phase: PHASE1
-
Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)
NCT03407170 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma
NCT03472027 ·Status: COMPLETED ·Phase: PHASE1